PURPOSE: To describe and analyze our experience with Anderson-Hynes transperitoneal laparoscopic pyeloplasty (LP) in the treatment of recurrent @entity4145 ( @entity4145 ). MATERIALS AND METHODS: 38 consecutive @entity1 who underwent transperitoneal laparoscopic redo-pyeloplasty between January 2007 and January 2015 at our department were included in the analysis. 36 @entity1 were previously treated with dismembered pyeloplasty and 2 @entity1 underwent a retrograde endopyelotomy. All @entity1 were symptomatic and all @entity1 had a @entity69133 minutes at pre-operative @entity5531 ( @entity21365 ) renal scan. All data were collected in a prospectively maintained database and retrospectively analyzed. Intraoperative and @entity260 have been reported according to the Satava and the Clavien-Dindo system. Treatment success was evaluated by a 12 month-postoperative renal scan. Total success was defined as T1/2<= 10 minutes while relative success was defined as T1/2between 10 to 20 minutes. Post-operative @entity3041 and @entity812 were also evaluated. RESULTS: Mean operating time was 103.16  30 minutes. The mean @entity190 was 122.37  73.25mL. The mean postoperative hospital stay was 4.47  0.86 days. No @entity3816 occurred. 6 out of 38 @entity1 (15.8%) experienced @entity260 . The success rate was 97.4% for @entity812 and 97.4% for @entity3041 . Post-operative renal scan showed radiological failure in one out of 38 (2.6%) @entity1 , relative success in 2 out of 38 (5.3%) @entity1 and total success in 35 out of 38 (92.1%) of @entity1 . CONCLUSION: Laparoscopic redo-pyeloplasty is a feasible procedure for the treatment of recurrent @entity4145 ( @entity4145 ), with a low rate of @entity532 and a high success rate in high laparoscopic volume centers.

Laparoscopic management of recurrent XXXX following pyeloplasty: a single surgical team experience with 38 cases.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity190 :: ('MESH:D006473', 'Disease') :: ['blood loss'] @entity812 :: ('MESH:D021501', 'Disease') :: ['flank pain'] @entity532 :: ('MESH:D003925', 'Disease') :: ['post-operative complications'] @entity260 :: ('MESH:D011183', 'Disease') :: ['postoperative complications'] @entity3041 :: ('MESH:D006869', 'Disease') :: ['hydronephrosis'] @entity21365 :: ('CHEBI:35745', 'Chemical') :: ['diethylene-triamine-pentaacetate'] @entity69133 :: ('1070638(Tax:209261)', 'Gene') :: ['T1/2>20'] @entity5531 :: ('MESH:D004369', 'Chemical') :: ['DTPA'] @entity4145 :: ('MESH:C537373', 'Disease') :: ['ureteropelvic junction obstruction', 'UPJO'] @entity3816 :: ('MESH:D007431', 'Disease') :: ['intraoperative complications']
@entity4145 :: (MESH:C537373,Disease) :: ['ureteropelvic junction obstruction']
